Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection

被引：0
|
作者：
Cody Orr
Wenjie Xu
Henry Masur
Shyam Kottilil
Eric G. Meissner
机构：
[1] Medical University of South Carolina,Division of Infectious Diseases
[2] Nanostring Technologies,Critical Care Medicine Department
[3] NIH Clinical Center,Division of Clinical Care and Research
[4] National Institutes of Health,Department of Microbiology and Immunology
[5] Institute of Human Virology,undefined
[6] University of Maryland School of Medicine,undefined
[7] Medical University of South Carolina,undefined
来源：
BMC Infectious Diseases | / 20卷
关键词：
Hepatitis C virus; Direct acting antiviral; Gene expression analysis; Sustained virologic response; Relapse;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies
    Lawitz, Eric
    Poordad, Fred
    Hyland, Robert H.
    Wang, Jing
    Liu, Lin
    Dvory-Sobol, Hadas
    Brainard, Diana M.
    McHutchison, John G.
    Gutierrez, Julio A.
    ANTIVIRAL THERAPY, 2016, 21 (08) : 679 - 687
  • [32] Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
    Sulkowski, Mark S.
    Vargas, Hugo E.
    Di Bisceglie, Adrian M.
    Kuo, Alexander
    Reddy, K. Rajender
    Lim, Joseph K.
    Morelli, Giuseppe
    Darling, Jama M.
    Feld, Jordan J.
    Brown, Robert S.
    Frazier, Lynn M.
    Stewart, Thomas G.
    Fried, Michael W.
    Nelson, David R.
    Jacobson, Ira M.
    GASTROENTEROLOGY, 2016, 150 (02) : 419 - 429
  • [33] Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin
    Korenaga, M.
    Izumi, N.
    Yokosuka, O.
    Takehara, T.
    Sakamoto, N.
    Nishiguchi, S.
    Ikeda, F.
    Yanase, M.
    Toyota, H.
    Genda, T.
    Umemura, T.
    Yatsuhashi, H.
    Ide, T.
    Toda, N.
    Nirei, K.
    Ueno, Y.
    Nishigaki, Y.
    Omata, M.
    Mizokami, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S23 - S23
  • [34] Safety of Ledipasvir/Sofosbuvir with and without Ribavirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials
    Alqahtani, Saleh
    Afdhal, Nezam H.
    Zeuzem, Stefan
    Gordon, Stuart C.
    Mangia, Alessandra
    Kwo, Paul Y.
    Yang, Jenny C.
    Ding, Xiao
    Pang, Phillip S.
    McHutchison, John G.
    Marcellin, Patrick
    Kowdley, Kris V.
    Sulkowski, Mark S.
    HEPATOLOGY, 2014, 60 : 1140A - 1141A
  • [35] Hepatocellular carcinoma development in Japanese patients with HCV genotype 1 infection who achieved sustained virologic response by ledipasvir/sofosbuvir and protease inhibitor with peginterferon plus ribavirin
    Korenaga, Masaaki
    Izumi, Namiki
    Yokosuka, Osamu
    Takehara, Tetsuo
    Sakamoto, Naoya
    Nishiguchi, Shuhei
    Ikeda, Fusao
    Yanase, Mikio
    Toyoda, Hidenori
    Genda, Takuya
    Umemura, Takeji
    Yatsuhashi, Hiroshi
    Ide, Tatsuya
    Toda, Nobuo
    Nirei, Kazushige
    Ueno, Yoshiyuki
    Nishigaki, Yoichi
    Nakane, Kunio
    Kanto, Tatsuya
    Omata, Masao
    Mizokami, Masashi
    HEPATOLOGY, 2017, 66 : 563A - 564A
  • [36] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
    Afdhal, Nezam
    Reddy, K. Rajender
    Nelson, David R.
    Lawitz, Eric
    Gordon, Stuart C.
    Schiff, Eugene
    Nahass, Ronald
    Ghalib, Reem
    Gitlin, Norman
    Herring, Robert
    Lalezari, Jacob
    Younes, Ziad H.
    Pockros, Paul J.
    Di Bisceglie, Adrian M.
    Arora, Sanjeev
    Subramanian, G. Mani
    Zhu, Yanni
    Dvory-Sobol, Hadas
    Yang, Jenny C.
    Pang, Phillip S.
    Symonds, William T.
    McHutchison, John G.
    Muir, Andrew J.
    Sulkowski, Mark
    Kwo, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16): : 1483 - 1493
  • [37] Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis (vol 22, pg 369, 2016)
    Ahmed, Hussien
    Elgebaly, Ahmed
    Abushouk, Abdelrahman Ibrahim
    Hammad, Ali Mohamed
    Attia, Attia
    Negida, Ahmed
    ANTIVIRAL THERAPY, 2017, 22 (05) : 457 - 457
  • [38] IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir
    O'Brien, Thomas R.
    Kottilil, Shyam
    Pfeiffer, Ruth M.
    GASTROENTEROLOGY, 2017, 153 (06) : 1694 - 1695
  • [39] Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection
    Osinusi, Anu
    Townsend, Kerry
    Kohli, Anita
    Nelson, Amy
    Seamon, Cassie
    Meissner, Eric G.
    Bon, Dimitra
    Silk, Rachel
    Gross, Chloe
    Price, Angie
    Sajadi, Mohammad
    Sidharthan, Sreetha
    Sims, Zayani
    Herrmann, Eva
    Hogan, John
    Teferi, Gebeyehu
    Talwani, Rohit
    Proschan, Michael
    Jenkins, Veronica
    Kleiner, David E.
    Wood, Brad J.
    Subramanian, G. Mani
    Pang, Phillip S.
    McHutchison, John G.
    Polis, Michael A.
    Fauci, Anthony S.
    Masur, Henry
    Kottilil, Shyam
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (12): : 1232 - 1239
  • [40] Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens
    Wilson, Eleanor M.
    Kattakuzhy, Sarah
    Sidharthan, Sreetha
    Sims, Zayani
    Tang, Lydia
    McLaughlin, Mary
    Price, Angie
    Nelson, Amy
    Silk, Rachel
    Gross, Chloe
    Akoth, Elizabeth
    Mo, Hongmei
    Subramanian, G. Mani
    Pang, Phillip S.
    McHutchison, John G.
    Osinusi, Anu
    Masur, Henry
    Kohli, Anita
    Kottilil, Shyam
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (03) : 280 - 288
12345